

Oreste Segatto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8407326/publications.pdf>

Version: 2024-02-01

37
papers

2,726
citations

279487

23
h-index

344852

36
g-index

39
all docs

39
docs citations

39
times ranked

2605
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends in Cancer, 2022, 8, 83-86.	3.8	6
2	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362.	1.8	35
3	Making sense of Cbp/p300 loss of function mutations in skin tumorigenesis. Journal of Pathology, 2020, 250, 3-6.	2.1	5
4	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	2.9	37
5	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology, 2019, 69, 131-142.	3.6	27
6	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	1.9	54
7	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. EMBO Molecular Medicine, 2018, 10, .	3.3	23
8	Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Cell, 2016, 165, 1031-1034.	13.5	1
9	Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Seminars in Cell and Developmental Biology, 2016, 50, 115-124.	2.3	20
10	Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS ONE, 2015, 10, e0129859.	1.1	8
11	Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015, 6, 35183-35201.	0.8	75
12	A pervasive role for MIG6 in restraining cell proliferation. Cell Death and Differentiation, 2014, 21, 345-347.	5.0	5
13	Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. Journal of Molecular Medicine, 2014, 92, 681-695.	1.7	15
14	Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis in Normal and Malignant Cells. , 2013, , 279-302.		1
15	Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. Journal of Cell Science, 2011, 124, 1785-1793.	1.2	87
16	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917.	3.3	109
17	A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. Journal of Cell Biology, 2010, 189, 557-571.	2.3	102
18	The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene, 2007, 26, 7833-7846.	2.6	67

#	ARTICLE	IF	CITATIONS
19	Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Wavedá€like phenotype. <i>EMBO Reports</i> , 2005, 6, 755-761.	2.0	44
20	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. <i>Oncogene</i> , 2005, 24, 4540-4548.	2.6	111
21	Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. <i>Experimental Cell Research</i> , 2005, 305, 343-354.	1.2	73
22	Feedback inhibition by RALT controls signal output by the ErbB network. <i>Oncogene</i> , 2003, 22, 4221-4234.	2.6	112
23	Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. <i>Oncogene</i> , 2002, 21, 6530-6539.	2.6	73
24	Negative regulation of receptor tyrosine kinase signals. <i>FEBS Letters</i> , 2001, 490, 132-141.	1.3	32
25	Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain. <i>Molecular and Cellular Biology</i> , 2000, 20, 7735-7750.	1.1	134
26	Expression of gp 185HER-2 in human cutaneous melanoma: Implications for experimental immunotherapeutics. <i>International Journal of Cancer</i> , 1994, 56, 341-346.	2.3	32
27	Production and Characterization of Murine mAbs to the Extracellular Domain of Human Neu Oncogene Product GP185HER2. <i>Hybridoma</i> , 1992, 11, 519-527.	0.9	31
28	Changes in expression of $\alpha 4 \beta 1$ integrin heterodimer in primary and metastatic breast cancer. <i>British Journal of Cancer</i> , 1992, 66, 318-322.	2.9	113
29	Cloning, expression, and biological effects of gene in mammalian cells. <i>Methods in Enzymology</i> , 1991, 198, 272-277.	0.4	6
30	EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. <i>Science</i> , 1990, 248, 79-83.	6.0	140
31	The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 3733-3737.	3.3	63
32	erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. <i>Science</i> , 1987, 237, 178-182.	6.0	972
33	Multiple epitope recognition: An approach to improved radioimmuno-detection of tumor-associated antigens. <i>International Journal of Cancer</i> , 1987, 39, 729-736.	2.3	19
34	Clinical improvement and partial correction of the T cell defects of acquired immunodeficiency syndrome (AIDS) and lymphadenopathy syndrome (LAS) by a calf thymus acid lysate. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 531-532.	0.9	4
35	Lymphoid stroma of Warthin's tumor: Phenotypic analogies with gut-associated lymphoid tissue. <i>Clinical Immunology and Immunopathology</i> , 1985, 34, 39-47.	2.1	9
36	Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. <i>Immunogenetics</i> , 1984, 19, 109-116.	1.2	77

#	ARTICLE	IF	CITATIONS
37	Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. Journal of Immunological Methods, 1983, 62, 337-346.	0.6	3